320 related articles for article (PubMed ID: 18927300)
1. Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR.
Oberthuer A; Kaderali L; Kahlert Y; Hero B; Westermann F; Berthold F; Brors B; Eils R; Fischer M
Clin Cancer Res; 2008 Oct; 14(20):6590-601. PubMed ID: 18927300
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma.
de Souza DR; Sanabani SS; de Souza AC; Filho Odone V; Epelman S; Bendit I
Pediatr Blood Cancer; 2011 May; 56(5):749-56. PubMed ID: 21154590
[TBL] [Abstract][Full Text] [Related]
3. Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling.
Schramm A; Schulte JH; Klein-Hitpass L; Havers W; Sieverts H; Berwanger B; Christiansen H; Warnat P; Brors B; Eils J; Eils R; Eggert A
Oncogene; 2005 Nov; 24(53):7902-12. PubMed ID: 16103881
[TBL] [Abstract][Full Text] [Related]
4. A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines.
Sugimoto T; Gotoh T; Yagyu S; Kuroda H; Iehara T; Hosoi H; Ohta S; Ohira M; Nakagawara A
Cancer Lett; 2013 Apr; 331(1):115-21. PubMed ID: 23268333
[TBL] [Abstract][Full Text] [Related]
5. Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.
Warnat P; Oberthuer A; Fischer M; Westermann F; Eils R; Brors B
BMC Cancer; 2007 May; 7():89. PubMed ID: 17531100
[TBL] [Abstract][Full Text] [Related]
6. Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients.
van Wezel EM; Decarolis B; Stutterheim J; Zappeij-Kannegieter L; Berthold F; Schumacher-Kuckelkorn R; Simon T; Fiocco M; van Noesel MM; Caron HN; van der Schoot CE; Hero B; Tytgat GAM
Eur J Cancer; 2016 Feb; 54():149-158. PubMed ID: 26796600
[TBL] [Abstract][Full Text] [Related]
7. Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers.
Oberthuer A; Juraeva D; Hero B; Volland R; Sterz C; Schmidt R; Faldum A; Kahlert Y; Engesser A; Asgharzadeh S; Seeger R; Ohira M; Nakagawara A; Scaruffi P; Tonini GP; Janoueix-Lerosey I; Delattre O; Schleiermacher G; Vandesompele J; Speleman F; Noguera R; Piqueras M; Bénard J; Valent A; Avigad S; Yaniv I; Grundy RG; Ortmann M; Shao C; Schwab M; Eils R; Simon T; Theissen J; Berthold F; Westermann F; Brors B; Fischer M
Clin Cancer Res; 2015 Apr; 21(8):1904-15. PubMed ID: 25231397
[TBL] [Abstract][Full Text] [Related]
8. Accurate prediction of neuroblastoma outcome based on miRNA expression profiles.
Schulte JH; Schowe B; Mestdagh P; Kaderali L; Kalaghatgi P; Schlierf S; Vermeulen J; Brockmeyer B; Pajtler K; Thor T; de Preter K; Speleman F; Morik K; Eggert A; Vandesompele J; Schramm A
Int J Cancer; 2010 Nov; 127(10):2374-85. PubMed ID: 20473924
[TBL] [Abstract][Full Text] [Related]
9. Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma.
Sahu D; Hsu CL; Lin CC; Yang TW; Hsu WM; Ho SY; Juan HF; Huang HC
Oncotarget; 2016 Sep; 7(36):58022-58037. PubMed ID: 27517149
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of MYCN and ID2 overexpression in neuroblastoma.
Alaminos M; Gerald WL; Cheung NK
Pediatr Blood Cancer; 2005 Dec; 45(7):909-15. PubMed ID: 16047351
[TBL] [Abstract][Full Text] [Related]
11. IGF2BP1 harbors prognostic significance by gene gain and diverse expression in neuroblastoma.
Bell JL; Turlapati R; Liu T; Schulte JH; Hüttelmaier S
J Clin Oncol; 2015 Apr; 33(11):1285-93. PubMed ID: 25753434
[TBL] [Abstract][Full Text] [Related]
12. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification.
Oberthuer A; Berthold F; Warnat P; Hero B; Kahlert Y; Spitz R; Ernestus K; König R; Haas S; Eils R; Schwab M; Brors B; Westermann F; Fischer M
J Clin Oncol; 2006 Nov; 24(31):5070-8. PubMed ID: 17075126
[TBL] [Abstract][Full Text] [Related]
13. Reanalysis of neuroblastoma expression profiling data using improved methodology and extended follow-up increases validity of outcome prediction.
Schramm A; Mierswa I; Kaderali L; Morik K; Eggert A; Schulte JH
Cancer Lett; 2009 Sep; 282(1):55-62. PubMed ID: 19349112
[TBL] [Abstract][Full Text] [Related]
14. Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis.
Murphy DM; Buckley PG; Bryan K; Watters KM; Koster J; van Sluis P; Molenaar J; Versteeg R; Stallings RL
Mol Carcinog; 2011 Jun; 50(6):403-11. PubMed ID: 21557326
[TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease in peripheral blood stem cell harvests from high-risk neuroblastoma patients.
Avigad S; Feinberg-Gorenshtein G; Luria D; Jeison M; Stein J; Grunshpan A; Sverdlov Y; Ash S; Yaniv I
J Pediatr Hematol Oncol; 2009 Jan; 31(1):22-6. PubMed ID: 19125082
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome.
Fischer M; Oberthuer A; Brors B; Kahlert Y; Skowron M; Voth H; Warnat P; Ernestus K; Hero B; Berthold F
Clin Cancer Res; 2006 Sep; 12(17):5118-28. PubMed ID: 16951229
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification.
Asgharzadeh S; Pique-Regi R; Sposto R; Wang H; Yang Y; Shimada H; Matthay K; Buckley J; Ortega A; Seeger RC
J Natl Cancer Inst; 2006 Sep; 98(17):1193-203. PubMed ID: 16954472
[TBL] [Abstract][Full Text] [Related]
18. MYCN RNA levels determined by quantitative in situ hybridization is better than MYCN gene dosages in predicting the prognosis of neuroblastoma patients.
Chang HH; Tseng YF; Lu MY; Yang YL; Chou SW; Lin DT; Lin KH; Jou ST; Hsu WM; Jeng YM
Mod Pathol; 2020 Apr; 33(4):531-540. PubMed ID: 31695155
[TBL] [Abstract][Full Text] [Related]
19. Molecular Classification Substitutes for the Prognostic Variables Stage, Age, and MYCN Status in Neuroblastoma Risk Assessment.
Rosswog C; Schmidt R; Oberthuer A; Juraeva D; Brors B; Engesser A; Kahlert Y; Volland R; Bartenhagen C; Simon T; Berthold F; Hero B; Faldum A; Fischer M
Neoplasia; 2017 Dec; 19(12):982-990. PubMed ID: 29091799
[TBL] [Abstract][Full Text] [Related]
20. Full-length telomerase reverse transcriptase messenger RNA is an independent prognostic factor in neuroblastoma.
Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
Am J Pathol; 2003 Mar; 162(3):1019-26. PubMed ID: 12598334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
